Humonix Biosciences

Humonix Biosciences has developed proprietary 3D human tissue models that mimic disease states ex vivo. These models are validated for key physiological characteristics and are used by pharma/biotech partners to screen drug candidates more efficiently than traditional animal models. The technology aims to reduce clinical trial failure risk by improving the translatability of preclinical data into clinical outcomes. The flagship glaucoma model has expanded into new areas such as retinal vascular dysfunction, pulmonary fibrosis, and renal fibrosis. No direct clinical results as the company does not develop therapeutics itself but supports others’ pipelines with its platform.